Sector
PharmaceuticalsOpen
₹19.15Prev. Close
₹19.21Turnover(Lac.)
₹3.9Day's High
₹19.69Day's Low
₹18.7652 Week's High
₹26.3552 Week's Low
₹16.2Book Value
₹3.35Face Value
₹10Mkt Cap (₹ Cr.)
15.33P/E
0EPS
0Divi. Yield
012 Sep 2023
12:00 AM
BookCloser
13 Feb 2024
12:00 AM
EGM
7 Sep 2024
12:00 AM
AGM
Announcement Date: 07 Sep, 2024
25 Sep 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 8.13 | 8.13 | 8.13 | 8.13 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -5.31 | 2.73 | 2.83 | 3.22 |
Net Worth | 2.82 | 10.86 | 10.96 | 11.35 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 8.16 | 197.39 | 79.71 | 61.88 |
yoy growth (%) | -95.86 | 147.63 | 28.8 | -1.67 |
Raw materials | -3.95 | -154.62 | -57.59 | -40.72 |
As % of sales | 48.36 | 78.33 | 72.24 | 65.8 |
Employee costs | -1.05 | -5.35 | -3.32 | -3.34 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 0.13 | 0.71 | 0.68 | 1.13 |
Depreciation | -0.28 | -1.95 | -1.68 | -1.7 |
Tax paid | 0.8 | -1.28 | 0 | -0.62 |
Working capital | -19.52 | -3.33 | 2.94 | 3.15 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -95.86 | 147.63 | 28.8 | -1.67 |
Op profit growth | -78.18 | 5.72 | -0.76 | -7.62 |
EBIT growth | -74.28 | -5.76 | 2.65 | -15.72 |
Net profit growth | -267.66 | -183.02 | 34.97 | -39.65 |
| Particulars (Rupees in Crores.) | Mar-2012 |
|---|---|
Gross Sales | 78.91 |
Excise Duty | 0 |
Net Sales | 78.91 |
Other Operating Income | 6.88 |
Other Income | 0.25 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,897 | 163.49 | 4,55,021.88 | 237.82 | 0.71 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,925 | 94.67 | 1,57,256.95 | 430 | 0.51 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,523.75 | 30.97 | 1,22,988.41 | 1,055.94 | 0.85 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,392.5 | 76.4 | 1,14,822.61 | 469 | 0.83 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,697.4 | 27.12 | 1,11,742.47 | 1,417.2 | 0.6 | 5,823.9 | 1,458.55 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
S Murali Krishna Murthy
Director
S Balaji Venkateswarlu
Whole Time Director & CFO
S Srinivas Kumar
Chairman & Independent Directo
J R K Panduranga Rao
Director
Gaddam Venkata Ramana
Director
Bhupathiraju S Raju
Independent Director
B Gopal Reddy
Independent Director
Murali Krishna Rayaprolu
Independent Director
Pottur Sujatha
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ortin Laboratories Ltd
Summary
Ortin Laboratories Limited was incorporated in October, 1986 with a nominal capital of Rs 1 lakh to offer quality Drugs and Medicines to the suffering mankind. The Company is a leading and predominant Pharmaceutical Manufacturer of Drugs and Medicines in India. The company is engaged in manufacture of Pharma formulations. They manufacture a range of pharmaceutical formulations of tablets, capsules, syrups, dry powders, and ointments in India. The company is having their manufacturing unit at Medak in Andhra Pradesh, which is equipped with technically modern manufacturing facilities to produce complete range of Pharmaceutical Formulations.The company offer anti arthritic drugs, antibiotics, chemo therapeutics, analgesics and antipyretics, cardiac and cardio vascular drugs, anti diarroheal drugs, anti depressants, anti hypertensive, anti aids, anti tuberculosis drugs, gynaecological drugs, antibiotics, anti diabetic, antacids anti ulcer drugs, anti allergics, anti-cold, decongestants, antioxidents, vitamins, minerals, anti bacterial drugs, anti emetics, anti helmenthetics, nutritional supplements and protein, and appetizers. They also produce dental, ophthalmology, pediatric, diuretics, dermatology, psychiatry, and ENT drugs. The company constructed a Factory in a spacious area of 25,000 sq feet with all ultra-modern infrastructure as per the WHO GMP Standards to manufacture the complete range of Pharmaceutical Formulations of tablets capsules syrups dry powders & ointments. Du
Read More
What is the Ortin Laboratories Ltd share price today?
The Ortin Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹18.85 today.
What is the Market Cap of Ortin Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ortin Laboratories Ltd is ₹15.33 Cr. as of 21 Oct ‘24
What is the PE and PB ratio of Ortin Laboratories Ltd?
The PE and PB ratios of Ortin Laboratories Ltd is 0 and 5.54 as of 21 Oct ‘24
What is the 52 Week High and Low of Ortin Laboratories Ltd?
The 52-week high/low is the highest and lowest price at which a Ortin Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ortin Laboratories Ltd is ₹16.2 and ₹26.35 as of 21 Oct ‘24
What is the CAGR of Ortin Laboratories Ltd?
Ortin Laboratories Ltd's CAGR for 5 Years at 14.33%, 3 Years at -15.95%, 1 Year at -2.33%, 6 Month at -2.58%, 3 Month at -1.82% and 1 Month at -10.87%.
What is the shareholding pattern of Ortin Laboratories Ltd?
The shareholding pattern of Ortin Laboratories Ltd is as follows:
Promoters - 1.23 %
Institutions - 6.25 %
Public - 92.52 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
